A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women
1상
완료
NCT07542847
| 대상 질환 | Healthy Volunteers |
|---|
| 임상 단계 | 1상 |
|---|
| 스폰서 | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 24 명 |
|---|
| 중재(약물) | OPC-167832, Itraconazole, Carbamazepine |
|---|
| 시작일 | 2022년 9월 19일 |
|---|
| 완료일 | 2022년 11월 18일 |
|---|
| 결과 공개일 | 2026년 6월 5일 |
|---|
요약
The purpose of this trial is to assess the potential for cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) with OPC-167832. The study is conducted in 2 parts: Part 1 assesses the potential effect of the CYP3A inhibitor itraconazole on the metabolism of OPC-167832 and Part 2 assesses the potential effect of the CYP3A inducer carbamazepine on the metabolism of OPC-167832 in healthy adult participants.
Part 1: Maximum Plasma Concentration (Cmax) of OPC-167832
Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15. · nanograms per milliliter (ng/mL)
| OPC-167832 | 81.0 ± 29.3 nanograms per milliliter (ng/mL) |
|---|
| OPC-167832 and Itraconazole | 144 ± 66.7 nanograms per milliliter (ng/mL) |
|---|
| Geometric Mean Ratio (GMR) | 1.723 (95% CI 1.410–2.106) |
|---|
Part 2: Cmax of OPC-167832
Predose and up to 168 hours postdose on Day 1; and Predose and up to 168 hours postdose on Day 25. · ng/mL
| OPC-167832 | 95.1 ± 36.6 ng/mL |
|---|
| OPC-167832 and Carbamazepine | 95.8 ± 32.9 ng/mL |
|---|
| GMR | 1.07 (95% CI 0.926–1.236) |
|---|
Part 1: Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of OPC-167832
Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15. · Nanograms*hours per milliliter (ng*h/mL)
| OPC-167832 | 2310 ± 898 Nanograms*hours per milliliter (ng*h/mL) |
|---|
| OPC-167832 and Itraconazole | 4490 ± 2390 Nanograms*hours per milliliter (ng*h/mL) |
|---|
| GMR | 1.82 (95% CI 1.568–2.113) |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.